Literature DB >> 22460074

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

Peter Valent1, Amy D Klion, Hans-Peter Horny, Florence Roufosse, Jason Gotlib, Peter F Weller, Andrzej Hellmann, Georgia Metzgeroth, Kristin M Leiferman, Michel Arock, Joseph H Butterfield, Wolfgang R Sperr, Karl Sotlar, Peter Vandenberghe, Torsten Haferlach, Hans-Uwe Simon, Andreas Reiter, Gerald J Gleich.   

Abstract

Eosinophilia is an important indicator of various neoplastic and nonneoplastic conditions. Depending on the underlying disease and mechanisms, eosinophil infiltration can lead to organ dysfunction, clinical symptoms, or both. During the past 2 decades, several different classifications of eosinophilic disorders and related syndromes have been proposed in various fields of medicine. Although criteria and definitions are, in part, overlapping, no global consensus has been presented to date. The Year 2011 Working Conference on Eosinophil Disorders and Syndromes was organized to update and refine the criteria and definitions for eosinophilic disorders and to merge prior classifications in a contemporary multidisciplinary schema. A panel of experts from the fields of immunology, allergy, hematology, and pathology contributed to this project. The expert group agreed on unifying terminologies and criteria and a classification that delineates various forms of hypereosinophilia, including primary and secondary variants based on specific hematologic and immunologic conditions, and various forms of the hypereosinophilic syndrome. For patients in whom no underlying disease or hypereosinophilic syndrome is found, the term hypereosinophilia of undetermined significance is introduced. The proposed novel criteria, definitions, and terminologies should assist in daily practice, as well as in the preparation and conduct of clinical trials.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22460074      PMCID: PMC4091810          DOI: 10.1016/j.jaci.2012.02.019

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  19 in total

Review 1.  Mechanisms of eosinophil-associated inflammation.

Authors:  G J Gleich
Journal:  J Allergy Clin Immunol       Date:  2000-04       Impact factor: 10.793

Review 2.  Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.

Authors:  Jason Gotlib; N C P Cross; D Gary Gilliland
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

Review 3.  Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders.

Authors:  Steven J Ackerman; Bruce S Bochner
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

Review 4.  Eosinophilia: secondary, clonal and idiopathic.

Authors:  Ayalew Tefferi; Mrinal M Patnaik; Animesh Pardanani
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

5.  Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.

Authors:  G Metzgeroth; C Walz; J Score; R Siebert; S Schnittger; C Haferlach; H Popp; T Haferlach; P Erben; J Mix; M C Müller; H Beneke; L Müller; F Del Valle; W E Aulitzky; G Wittkowsky; N Schmitz; C Schulte; K Müller-Hermelink; E Hodges; S J Whittaker; F Diecker; H Döhner; P Schuld; R Hehlmann; A Hochhaus; N C P Cross; A Reiter
Journal:  Leukemia       Date:  2007-03-22       Impact factor: 11.528

Review 6.  The hypereosinophilic syndromes: still more heterogeneity.

Authors:  Gerald J Gleich; Kristin M Leiferman
Journal:  Curr Opin Immunol       Date:  2005-10-07       Impact factor: 7.486

Review 7.  Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.

Authors:  Florence Roufosse; Michel Goldman; Elie Cogan
Journal:  Semin Respir Crit Care Med       Date:  2006-04       Impact factor: 3.119

Review 8.  Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.

Authors:  Barbara J Bain
Journal:  Am J Hematol       Date:  2004-09       Impact factor: 10.047

9.  Eosinophil infiltration and degranulation in normal human tissue.

Authors:  M Kato; G M Kephart; N J Talley; J M Wagner; M G Sarr; M Bonno; T W McGovern; G J Gleich
Journal:  Anat Rec       Date:  1998-11

10.  Familial eosinophilia: a benign disorder?

Authors:  Amy D Klion; Melissa A Law; William Riemenschneider; Mary Lou McMaster; Margaret R Brown; McDonald Horne; Barbara Karp; Michael Robinson; Vandana Sachdev; Eben Tucker; Maria Turner; Thomas B Nutman
Journal:  Blood       Date:  2004-02-26       Impact factor: 22.113

View more
  159 in total

1.  A Case of Erythroderma Secondary to Hypereosinophilia.

Authors:  Mohammed Shafi Abdulsalam; Hari Chandana Ghanta; Prabu Pandurangan; Maya Menon; Sheba S K Jacob
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation.

Authors:  Alice Soragni; Shida Yousefi; Christina Stoeckle; Angela B Soriaga; Michael R Sawaya; Evelyne Kozlowski; Inès Schmid; Susanne Radonjic-Hoesli; Sebastien Boutet; Garth J Williams; Marc Messerschmidt; M Marvin Seibert; Duilio Cascio; Nadia A Zatsepin; Manfred Burghammer; Christian Riekel; Jacques-Philippe Colletier; Roland Riek; David S Eisenberg; Hans-Uwe Simon
Journal:  Mol Cell       Date:  2015-02-26       Impact factor: 17.970

Review 3.  Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.

Authors:  Amy Klion
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 4.  Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.

Authors:  Zhaleh J Amini-Vaughan; Margarita Martinez-Moczygemba; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

Review 5.  Therapeutic approaches to patients with hypereosinophilic syndromes.

Authors:  Hans-Uwe Simon; Amy Klion
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

6.  [Hypereosinophilic syndrome].

Authors:  F Moosig; G Richardt; C Merten; W L Gross
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

Review 7.  Eosinophilic Vasculitis.

Authors:  Karen L Vega Villanueva; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2020-01-11       Impact factor: 4.592

Review 8.  Common and Novel Markers for Measuring Inflammation and Oxidative Stress Ex Vivo in Research and Clinical Practice-Which to Use Regarding Disease Outcomes?

Authors:  Alain Menzel; Hanen Samouda; Francois Dohet; Suva Loap; Mohammed S Ellulu; Torsten Bohn
Journal:  Antioxidants (Basel)       Date:  2021-03-09

9.  Recurrent severe acute hepatitis caused by hypereosinophilic syndrome associated with elevated serum immunoglobulin G4 levels.

Authors:  Tomonori Aoyama; Toshiharu Matsumoto; Akira Uchiyama; Kazuyoshi Kon; Shunhei Yamashina; Satoko Suzuki; Kenichi Ikejima; Takashi Yao; Ryohei Kuwatsuru; Sumio Watanabe
Journal:  Clin J Gastroenterol       Date:  2014-10-16

Review 10.  [IgG4-related disease].

Authors:  J Loock; B Manger
Journal:  Z Rheumatol       Date:  2013-03       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.